Pentraxins: CRP and PTX3 and cardiovascular disease

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 4, 2011, Pages 229-235

  Maekawa, Yuichiro ^a   Nagai, Toshiyuki ^a   Anzai, Atsushi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Cardiovascular disease; Pentraxin3

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN E3; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PENTRAXIN 3; SERUM AMYLOID P; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; FIBROBLAST; GENE CONTROL; HEART FAILURE; HEART MUSCLE CELL; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STRUCTURE; SMOOTH MUSCLE FIBER; ST SEGMENT ELEVATION; VASCULAR SMOOTH MUSCLE;

EID: 79959936662     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811796117744     Document Type: Article

References (78)

1. Matzinger, P. The danger model: a renewed sense of self. Science, 2002, 296 (5566), 301-305.
2. Libby, P.; Ridker, P. M.; Hansson, G. K. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol., 2009, 54 (23), 2129-2138.
3. Fuse, K.; Chan, G.; Liu, Y.; Gudgeon, P.; Husain, M.; Chen, M.; Yeh, W. C.; Akira, S.; Liu, P. P. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation, 2005, 112 (15), 2276-2285.
4. Marty, R. R.; Dirnhofer, S.; Mauermann, N.; Schweikert, S.; Akira, S.; Hunziker, L.; Penninger, J. M.; Eriksson, U. MyD88 signaling controls autoimmune myocarditis induction. Circulation, 2006, 113 (2), 258-265.
5. Maekawa, Y.; Ouzounian, M.; Opavsky, M. A.; Liu, P. P. Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity. Circulation, 2007, 115 (1), 5-8.
6. Maekawa, Y.; Mizue, N.; Chan, A.; Shi, Y.; Liu, Y.; Dawood, S.; Chen, M.; Dawood, F.; de Couto, G.; Li, G. H.; Suzuki, N.; Yeh, W. C.; Gramolini, A.; Medin, J. A.; Liu, P. P. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation, 2009, 120 (14), 1401-1414.
7. Shishido, T.; Nozaki, N.; Yamaguchi, S.; Shibata, Y.; Nitobe, J.; Miyamoto, T.; Takahashi, H.; Arimoto, T.; Maeda, K.; Yamakawa, M.; Takeuchi, O.; Akira, S.; Takeishi, Y.; Kubota, I. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation, 2003, 108 (23), 2905-2910.
8. Bottazzi, B.; Doni, A.; Garlanda, C.; Mantovani, A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol., 2010, 28, 157-183.
9. Alles, V. V.; Bottazzi, B.; Peri, G.; Golay, J.; Introna, M.; Mantovani, A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood, 1994, 84 (10), 3483-3493.
10. Thompson, D.; Pepys, M. B.; Wood, S. P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 1999, 7 (2), 169-177.
11. Shrive, A. K.; Cheetham, G. M.; Holden, D.; Myles, D. A.; Turnell, W. G.; Volanakis, J. E.; Pepys, M. B.; Bloomer, A. C.; Greenhough, T. J. Three dimensional structure of human C-reactive protein. Nat. Struct. Biol., 1996, 3 (4), 346-354.
12. Garlanda, C.; Bottazzi, B.; Bastone, A.; Mantovani, A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol., 2005, 23, 337-366.
13. Du Clos, T. W.; Mold, C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res., 2004, 30 (3), 261-277.
14. Patel, D. N.; King, C. A.; Bailey, S. R.; Holt, J. W.; Venkatachalam, K.; Agrawal, A.; Valente, A. J.; Chandrasekar, B. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J. Biol. Chem., 2007, 282 (37), 27229-27238.
15. Jabs, W. J.; Theissing, E.; Nitschke, M.; Bechtel, J. F.; Duchrow, M.; Mohamed, S.; Jahrbeck, B.; Sievers, H. H.; Steinhoff, J.; Bartels, C. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation, 2003, 108 (12), 1428-1431.
16. Yasojima, K.; Schwab, C.; McGeer, E. G.; McGeer, P. L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol., 2001, 158 (3), 1039-1051.
17. Pepys, M. B.; Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest., 2003, 111 (12), 1805-1812.
18. Ridker, P. M.; Hennekens, C. H.; Buring, J. E.; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 2000, 342 (12), 836-843.
19. Aukrust, P.; Halvorsen, B.; Yndestad, A.; Ueland, T.; Oie, E.; Otterdal, K.; Gullestad, L.; Damas, J. K. Chemokines and cardiovascular risk. Arterioscler. Thromb. Vasc. Biol., 2008, 28 (11), 1909-1919.
20. Morrow, D. A.; de Lemos, J. A.; Sabatine, M. S.; Wiviott, S. D.; Blazing, M. A.; Shui, A.; Rifai, N.; Califf, R. M.; Braunwald, E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation, 2006, 114 (4), 281-288.
21. McMurray, J. J.; Kjekshus, J.; Gullestad, L.; Dunselman, P.; Hjalmarson, A.; Wedel, H.; Lindberg, M.; Waagstein, F.; Grande, P.; Hradec, J.; Kamensky, G.; Korewicki, J.; Kuusi, T.; Mach, F.; Ranjith, N.; Wikstrand, J. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation, 2009, 120 (22), 2188-2196.
22. Ridker, P. M.; Cannon, C. P.; Morrow, D.; Rifai, N.; Rose, L. M.; McCabe, C. H.; Pfeffer, M. A.; Braunwald, E. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med., 2005, 352 (1), 20-28.
23. Anzai, T.; Yoshikawa, T.; Kaneko, H.; Maekawa, Y.; Iwanaga, S.; Asakura, Y.; Ogawa, S. Association between serum C-reactive protein elevation and left ventricular thrombus formation after first anterior myocardial infarction. Chest, 2004, 125 (2), 384-389.
24. Anzai, T.; Yoshikawa, T.; Shiraki, H.; Asakura, Y.; Akaishi, M.; Mitamura, H.; Ogawa, S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation, 1997, 96 (3), 778-784.
25. Takahashi, T.; Anzai, T.; Yoshikawa, T.; Maekawa, Y.; Asakura, Y.; Satoh, T.; Mitamura, H.; Ogawa, S. Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction--role of neurohormones and cytokines. Int. J. Cardiol., 2003, 88 (2-3), 257-265.
26. Pasceri, V.; Willerson, J. T.; Yeh, E. T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102 (18), 2165-2168.
27. Pasceri, V.; Cheng, J. S.; Willerson, J. T.; Yeh, E. T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation, 2001, 103 (21), 2531-2534.
28. Verma, S.; Wang, C. H.; Li, S. H.; Dumont, A. S.; Fedak, P. W.; Badiwala, M. V.; Dhillon, B.; Weisel, R. D.; Li, R. K.; Mickle, D. A.; Stewart, D. J. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002, 106 (8), 913-919.
29. Wang, C. H.; Li, S. H.; Weisel, R. D.; Fedak, P. W.; Dumont, A. S.; Szmitko, P.; Li, R. K.; Mickle, D. A.; Verma, S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation, 2003, 107 (13), 1783-1790.
30. Verma, S.; Kuliszewski, M. A.; Li, S. H.; Szmitko, P. E.; Zucco, L.; Wang, C. H.; Badiwala, M. V.; Mickle, D. A.; Weisel, R. D.; Fedak, P. W.; Stewart, D. J.; Kutryk, M. J. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation, 2004, 109 (17), 2058-2067.
31. Montero, I.; Orbe, J.; Varo, N.; Beloqui, O.; Monreal, J. I.; Rodriguez, J. A.; Diez, J.; Libby, P.; Paramo, J. A. C-reactive protein induces matrix metalloproteinase-1 and-10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J. Am. Coll. Cardiol., 2006, 47 (7), 1369-1378.
32. Chang, M. K.; Binder, C. J.; Torzewski, M.; Witztum, J. L. Creactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. USA., 2002, 99 (20), 13043-13048.
33. Eisenhardt, S. U.; Habersberger, J.; Murphy, A.; Chen, Y. C.; Woollard, K. J.; Bassler, N.; Qian, H.; von Zur Muhlen, C.; Hagemeyer, C. E.; Ahrens, I.; Chin-Dusting, J.; Bobik, A.; Peter, K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ. Res., 2009, 105 (2), 128-137.
34. Li, S. H.; Szmitko, P. E.; Weisel, R. D.; Wang, C. H.; Fedak, P. W.; Li, R. K.; Mickle, D. A.; Verma, S. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation, 2004, 109 (7), 833-836.
35. Bhakdi, S.; Torzewski, M.; Paprotka, K.; Schmitt, S.; Barsoom, H.; Suriyaphol, P.; Han, S. R.; Lackner, K. J.; Husmann, M. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation, 2004, 109 (15), 1870-1876.
36. Schwedler, S. B.; Filep, J. G.; Galle, J.; Wanner, C.; Potempa, L. A. C-reactive protein: a family of proteins to regulate cardiovascular function. Am. J. Kidney Dis., 2006, 47 (2), 212-222.
37. Black, S.; Kushner, I.; Samols, D. C-reactive Protein. J. Biol. Chem., 2004, 279 (47), 48487-48490.
38. Casas, J. P.; Shah, T.; Hingorani, A. D.; Danesh, J.; Pepys, M. B. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med., 2008, 264 (4), 295-314.
39. Danenberg, H. D.; Szalai, A. J.; Swaminathan, R. V.; Peng, L.; Chen, Z.; Seifert, P.; Fay, W. P.; Simon, D. I.; Edelman, E. R. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation, 2003, 108 (5), 512-515.
40. Paul, A.; Ko, K. W.; Li, L.; Yechoor, V.; McCrory, M. A.; Szalai, A. J.; Chan, L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2004, 109 (5), 647-655.
41. Grad, E.; Golomb, M.; Mor-Yosef, I.; Koroukhov, N.; Lotan, C.; Edelman, E. R.; Danenberg, H. D. Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. Am J Physiol. Heart Circ. Physiol., 2007, 293 (1), H489-495.
42. Trion, A.; de Maat, M. P.; Jukema, J. W.; van der Laarse, A.; Maas, M. C.; Offerman, E. H.; Havekes, L. M.; Szalai, A. J.; Princen, H. M.; Emeis, J. J. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler. Thromb. Vasc. Biol., 2005, 25 (8), 1635-1640.
43. Kovacs, A.; Tornvall, P.; Nilsson, R.; Tegner, J.; Hamsten, A.; Bjorkegren, J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc. Natl. Acad. Sci. USA., 2007, 104 (34), 13768-13773.
44. Ikeda, U.; Maeda, Y.; Yamamoto, K.; Shimada, K. C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc. Res., 2002, 56 (1), 86-92.
45. Zhang, R.; Zhang, Y. Y.; Huang, X. R.; Wu, Y.; Chung, A. C.; Wu, E. X.; Szalai, A. J.; Wong, B. C.; Lau, C. P.; Lan, H. Y. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension, 2010, 55 (4), 953-960.
46. Mold, C.; Gewurz, H.; Du Clos, T. W. Regulation of complement activation by C-reactive protein. Immunopharmacology, 1999, 42 (1-3), 23-30.
47. Breviario, F.; d'Aniello, E. M.; Golay, J.; Peri, G.; Bottazzi, B.; Bairoch, A.; Saccone, S.; Marzella, R.; Predazzi, V.; Rocchi, M. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J. Biol. Chem., 1992, 267 (31), 22190-22197.
48. Lee, G. W.; Lee, T. H.; Vilcek, J. TSG-14, a tumor necrosis factorand IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J. Immunol., 1993, 150 (5), 1804-1812.
49. Introna, M.; Alles, V. V.; Castellano, M.; Picardi, G.; De Gioia, L.; Bottazzai, B.; Peri, G.; Breviario, F.; Salmona, M.; De Gregorio, L.; Dragani, T. A.; Srinivasan, N.; Blundell, T. L.; Hamilton, T. A.; Mantovani, A. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood, 1996, 87 (5), 1862-1872.
50. Bottazzi, B.; Vouret-Craviari, V.; Bastone, A.; De Gioia, L.; Matteucci, C.; Peri, G.; Spreafico, F.; Pausa, M.; D'Ettorre, C.; Gianazza, E.; Tagliabue, A.; Salmona, M.; Tedesco, F.; Introna, M.; Mantovani, A. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J. Biol. Chem., 1997, 272 (52), 32817-32823.
51. Bottazzi, B.; Garlanda, C.; Cotena, A.; Moalli, F.; Jaillon, S.; Deban, L.; Mantovani, A. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol. Rev., 2009, 227 (1), 9-18.
52. Perrier, P.; Martinez, F. O.; Locati, M.; Bianchi, G.; Nebuloni, M.; Vago, G.; Bazzoni, F.; Sozzani, S.; Allavena, P.; Mantovani, A. Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-activating chemokine, CXC chemokine ligand 13. J. Immunol., 2004, 172 (11), 7031-7042.
53. Polentarutti, N.; Picardi, G.; Basile, A.; Cenzuales, S.; Rivolta, A.; Matteucci, C.; Peri, G.; Mantovani, A.; Introna, M. Interferongamma inhibits expression of the long pentraxin PTX3 in human monocytes. Eur. J. Immunol., 1998, 28 (2), 496-501.
54. Jaillon, S.; Peri, G.; Delneste, Y.; Fremaux, I.; Doni, A.; Moalli, F.; Garlanda, C.; Romani, L.; Gascan, H.; Bellocchio, S.; Bozza, S.; Cassatella, M. A.; Jeannin, P.; Mantovani, A. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J. Exp. Med., 2007, 204 (4), 793-804.
55. Klouche, M.; Peri, G.; Knabbe, C.; Eckstein, H. H.; Schmid, F. X.; Schmitz, G.; Mantovani, A. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis, 2004, 175 (2), 221-228.
56. Rolph, M. S.; Zimmer, S.; Bottazzi, B.; Garlanda, C.; Mantovani, A.; Hansson, G. K. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol., 2002, 22 (5), e10-14.
57. Bosutti, A.; Grassi, G.; Zanetti, M.; Aleksova, A.; Zecchin, M.; Sinagra, G.; Biolo, G.; Guarnieri, G. Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients. Clin. Exp. Med., 2007, 7 (1), 16-23.
58. Nebuloni, M.; Pasqualini, F.; Zerbi, P.; Lauri, E.; Mantovani, A.; Vago, L.; Garlanda, C. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc. Pathol., 2011, 20 (1), e27-35.
59. Peri, G.; Introna, M.; Corradi, D.; Iacuitti, G.; Signorini, S.; Avanzini, F.; Pizzetti, F.; Maggioni, A. P.; Moccetti, T.; Metra, M.; Cas, L. D.; Ghezzi, P.; Sipe, J. D.; Re, G.; Olivetti, G.; Mantovani, A.; Latini, R. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation, 2000, 102 (6), 636-641.
60. Rovere, P.; Peri, G.; Fazzini, F.; Bottazzi, B.; Doni, A.; Bondanza, A.; Zimmermann, V. S.; Garlanda, C.; Fascio, U.; Sabbadini, M. G.; Rugarli, C.; Mantovani, A.; Manfredi, A. A. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood, 2000, 96 (13), 4300-4306.
61. Libby, P.; Hansson, G. K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest., 1991, 64 (1), 5-15.
62. Hansson, G. K.; Libby, P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 2006, 6 (7), 508-519.
63. Savchenko, A.; Imamura, M.; Ohashi, R.; Jiang, S.; Kawasaki, T.; Hasegawa, G.; Emura, I.; Iwanari, H.; Sagara, M.; Tanaka, T.; Hamakubo, T.; Kodama, T.; Naito, M. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J. Pathol., 2008, 215 (1), 48-55.
64. Norata, G. D.; Marchesi, P.; Pulakazhi Venu, V. K.; Pasqualini, F.; Anselmo, A.; Moalli, F.; Pizzitola, I.; Garlanda, C.; Mantovani, A.; Catapano, A. L. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation, 2009, 120 (8), 699-708.
65. Norata, G. D.; Marchesi, P.; Pirillo, A.; Uboldi, P.; Chiesa, G.; Maina, V.; Garlanda, C.; Mantovani, A.; Catapano, A. L. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb. Vasc. Biol., 2008, 28 (5), 925-931.
66. Latini, R.; Maggioni, A. P.; Peri, G.; Gonzini, L.; Lucci, D.; Mocarelli, P.; Vago, L.; Pasqualini, F.; Signorini, S.; Soldateschi, D.; Tarli, L.; Schweiger, C.; Fresco, C.; Cecere, R.; Tognoni, G.; Mantovani, A. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation, 2004, 110 (16), 2349-2354.
67. Matsui, S.; Ishii, J.; Kitagawa, F.; Kuno, A.; Hattori, K.; Ishikawa, M.; Okumura, M.; Kan, S.; Nakano, T.; Naruse, H.; Tanaka, I.; Nomura, M.; Hishida, H.; Ozaki, Y. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis, 2010, 210 (1), 220-225.
68. Brugger-Andersen, T.; Ponitz, V.; Kontny, F.; Staines, H.; Grundt, H.; Sagara, M.; Nilsen, D. W. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain. Thromb. Haemost., 2009, 102 (3), 555-563.
69. Ohbayashi, H.; Miyazawa, C.; Miyamoto, K.; Sagara, M.; Yamashita, T.; Onda, R. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J. Atheroscler. Thromb., 2009, 16 (4), 490-500.
70. Yilmaz, M. I.; Axelsson, J.; Sonmez, A.; Carrero, J. J.; Saglam, M.; Eyileten, T.; Caglar, K.; Kirkpantur, A.; Celik, T.; Oguz, Y.; Vural, A.; Yenicesu, M.; Lindholm, B.; Stenvinkel, P. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin. J. Am. Soc. Nephrol., 2009, 4 (3), 535-541.
71. Griselli, M.; Herbert, J.; Hutchinson, W. L.; Taylor, K. M.; Sohail, M.; Krausz, T.; Pepys, M. B. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J. Exp. Med., 1999, 190 (12), 1733-1740.
72. Salio, M.; Chimenti, S.; De Angelis, N.; Molla, F.; Maina, V.; Nebuloni, M.; Pasqualini, F.; Latini, R.; Garlanda, C.; Mantovani, A. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation, 2008, 117 (8), 1055-1064.
73. Nian, M.; Lee, P.; Khaper, N.; Liu, P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res., 2004, 94 (12), 1543-1553.
74. Torre-Amione, G. Immune activation in chronic heart failure. Am. J. Cardiol., 2005, 95 (11A), 3C-8C; discussion 38C-40C.
75. Kalogeropoulos, A.; Georgiopoulou, V.; Psaty, B. M.; Rodondi, N.; Smith, A. L.; Harrison, D. G.; Liu, Y.; Hoffmann, U.; Bauer, D. C.; Newman, A. B.; Kritchevsky, S. B.; Harris, T. B.; Butler, J. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J. Am. Coll. Cardiol., 2010, 55 (19), 2129-2137.
76. von Haehling, S.; Schefold, J. C.; Lainscak, M.; Doehner, W.; Anker, S. D. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin., 2009, 5 (4), 549-560.
77. Maekawa, Y.; Anzai, T.; Yoshikawa, T.; Asakura, Y.; Takahashi, T.; Ishikawa, S.; Mitamura, H.; Ogawa, S. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am. Coll. Cardiol., 2002, 39 (2), 241-246.
78. Suzuki, S.; Takeishi, Y.; Niizeki, T.; Koyama, Y.; Kitahara, T.; Sasaki, T.; Sagara, M.; Kubota, I. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am. Heart. J., 2008, 155 (1), 75-81.